Siegfried Holding AG
SFZN
Hisse Senetlerindeki Sıralama
#4106
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Hisse Fiyatı
$88.34
Piyasa Değeri
$3.87B
Değişim (1 gün)
1.68%
Değişim (1 yıl)
-12.97%
Ülke
CH
Ticaret Siegfried Holding AG (SFZN)
Kategori
Healthcare
Siegfried Holding AG (SFZN) için gelir
Oct 2026 itibarıyla gelir TTM: 0
Siegfried Holding AG şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) 0'dir. 2026 yılında şirketin geliri 0 önceki yıla eşit 2026 yılındaki 0 gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Siegfried Holding AG için 2002 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2025 | $1.67B | 16.75% |
| 2024 | $1.43B | -5.21% |
| 2023 | $1.51B | 13.69% |
| 2022 | $1.33B | 9.98% |
| 2021 | $1.21B | 28.54% |
| 2020 | $940.74M | 9.18% |
| 2019 | $861.60M | 6.71% |
| 2018 | $807.42M | 4.86% |
| 2017 | $770.00M | 9.19% |
| 2016 | $705.17M | 46.67% |
| 2015 | $480.78M | 51.48% |
| 2014 | $317.39M | -24.47% |
| 2013 | $420.19M | 4.56% |
| 2012 | $401.86M | 15.06% |
| 2011 | $349.27M | 3.82% |
| 2010 | $336.43M | 22.82% |
| 2009 | $273.92M | 1.32% |
| 2008 | $270.33M | -4.00% |
| 2007 | $281.59M | 14.52% |
| 2006 | $245.88M | 1.65% |
| 2005 | $241.89M | -14.43% |
| 2004 | $282.67M | -4.53% |
| 2003 | $296.08M | 2.63% |
| 2002 | $288.49M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
